ConductScience.org, home

Paper1997108

Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.

Pichert G and 3 others. Br J Cancer, 1991. Cited by 49 papers, by iCite.

Cite this record

ConductScience Library. Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma. Papers, record 1997108. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1997108

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.
PubMed
Journal
Br J Cancer
PubMed
Year
1991
PubMed
Publication types
Clinical Trial, Journal Article, Multicenter Study
PubMed
Citations, by iCite
49
iCite
Relative citation ratio, by iCite
1.73
iCite
Revised in PubMed
2019-05-15
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Pichert GG
2Jost LML M
3Fierz WW
4Stahel RAR A

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Renal CellMajor topic
Interferon-alphaMajor topic
Interleukin-2Major topic
Kidney NeoplasmsMajor topic
MelanomaMajor topic
Adult
Drug Administration Schedule
Female
HLA-DR Antigens
Humans
Interferon alpha-2
Killer Cells, Lymphokine-Activated
Killer Cells, Natural
Male
Middle Aged
Recombinant Proteins

Source PubMed

Download CSV of topics

References22

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
14056843Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma.J Clin Oncol1985https://conductscience.org/library/papers/4056843PubMed
22390468Thyroiditis after treatment with interleukin-2 and interferon alpha-2a.Br J Cancer1990https://conductscience.org/library/papers/2390468PubMed
33828990Direct antiproliferative effects of recombinant human interferon-alpha B/D hybrids on human tumor cell lines.Cancer Res1987https://conductscience.org/library/papers/3828990PubMed
43497883In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells.Int J Cancer1987https://conductscience.org/library/papers/3497883PubMed
53258138Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.Ann Intern Med1988https://conductscience.org/library/papers/3258138PubMed
63285747NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.Ann Intern Med1988https://conductscience.org/library/papers/3285747PubMed
73259674Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells.N Engl J Med1988https://conductscience.org/library/papers/3259674PubMed
83131876Interleukin-2: inception, impact, and implications.Science1988https://conductscience.org/library/papers/3131876PubMed
92493053Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumor infiltrating lymphocytes.J Immunol1989https://conductscience.org/library/papers/2493053PubMed
102647913A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma.J Clin Oncol1989https://conductscience.org/library/papers/2647913PubMed
112787749Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumors.Eur J Cancer Clin Oncol1989https://conductscience.org/library/papers/2787749PubMed
122809685Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study.J Clin Oncol1989https://conductscience.org/library/papers/2809685PubMed
132685181Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.J Clin Oncol1989https://conductscience.org/library/papers/2685181PubMed
142598190The inhibitory effect of human interferon alpha on the generation of lymphokine-activated killer activity.Cancer Immunol Immunother1989https://conductscience.org/library/papers/2598190PubMed
15181845Selective in vitro growth of T lymphocytes from normal human bone marrows.Science1976https://conductscience.org/library/papers/181845PubMed
166175788Systemic administration of human leukocyte interferon to melanoma patients. II. Cellular events associated with changes in natural killer cytotoxicity.J Natl Cancer Inst1982https://conductscience.org/library/papers/6175788PubMed
176403867Structure and expression of a cloned cDNA for human interleukin-2.Nature1983https://conductscience.org/library/papers/6403867PubMed
186413638Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.J Exp Med1983https://conductscience.org/library/papers/6413638PubMed
193873953Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma.Br J Cancer1985https://conductscience.org/library/papers/3873953PubMed
202156163An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy.N Engl J Med1990https://conductscience.org/library/papers/2156163PubMed

See all 22 referencesDownload CSV of references

Cited by9

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 49 citations.

PMIDTitleJournalYearIn PapersSource
31340613Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors.Cancers (Basel)2019https://conductscience.org/library/papers/31340613PubMed
30691103Incidence of Capillary Leak Syndrome as an Adverse Effect of Drugs in Cancer Patients: A Systematic Review and Meta-Analysis.J Clin Med2019https://conductscience.org/library/papers/30691103PubMed
28337194IL-1β, IL-8, and Matrix Metalloproteinases-1, -2, and -10 Are Enriched upon Monocyte-Breast Cancer Cell Cocultivation in a Matrigel-Based Three-Dimensional System.Front Immunol2017https://conductscience.org/library/papers/28337194PubMed
23982524The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.Nat Rev Clin Oncol2013https://conductscience.org/library/papers/23982524PubMed
8408187Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapy.J Cancer Res Clin Oncol1993https://conductscience.org/library/papers/8408187PubMed
8306366Relationship between soluble tumor necrosis factor (TNF) receptors and TNF alpha during immunotherapy with interleukin-2 and/or interferon alpha.Cancer Immunol Immunother1994https://conductscience.org/library/papers/8306366PubMed
7678979Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy.Br J Cancer1993https://conductscience.org/library/papers/7678979PubMed
1419647Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer.Br J Cancer1992https://conductscience.org/library/papers/1419647PubMed
1418698Clinical toxicity of interleukin-2.Drug Saf1992https://conductscience.org/library/papers/1418698PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ALPK180216PubTator's text mininghttps://conductscience.org/library/genes/80216NCBI Gene
IFNA23440PubTator's text mininghttps://conductscience.org/library/genes/3440NCBI Gene
IL23558PubTator's text mininghttps://conductscience.org/library/genes/3558NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/1997108

GET https://conductscience.org/api/papers/v1/1997108/references?page=2